Cofounder and CEO Veracyte®
NuGEN has been a valued partner in the development and commercialization of Afirma® Thyroid FNA Analysis. NuGEN’s sample preparation technology is a critical component in addressing the challenges of extracting genomic information from small, fine needle aspirate biopsies. Their dependable supply, quality and excellent customer service provides us with the assurance we need in pioneering the development of novel molecular diagnostic tests.
Associate Scientist California Pacific Medical Center Research Institute
My colleagues and I are using high-throughput sequencing methods to study age-related diseases and have employed the Ovation® Target Enrichment System for targeted sequencing and identification of genetic variants. In conjunction with this method, we have utilized the Ovation® Target Enrichment Data Processing Application for BaseSpace to perform data analysis. We found the application to be a valuable tool for eliminating bottlenecks associated with basic data processing. The application aids our studies by streamlining data analysis and accelerating the understanding of the functional impact of genetic variants on the underlying processes of age-related diseases.
Associate Director of Molecular Biology at AbbVie Stemcentrx
A lung adenocarcinoma tumor that was determined to have an ALK rearrangement by clinical SNaPshot Genotyping (multiplex PCR assay) was grown as a patient-derived xenograft model. Using NuGEN’s fusion detection workflow, the tumor was confirmed to have an EML4-ALK fusion after two passages in mice
Director at Avera Cancer Institute for Precision Oncology Genomics Laboratory
The Ovation Fusion Detection BaseSpace Application in conjunction with NuGEN’s comprehensive fusion panel provides a simple start to finish workflow. This solution helps us to not only identify clinically actionable fusions but also to perform basic research to study how other fusions may be relevant to cancer progression and prognosis in a single assay.
Dr. Tranah is a Professor at the California Pacific Medical Center (CPMC) Research Institute and an Adjunct Professor in the Department of Epidemiology and Biostatistics at the University of California, San Francisco. Dr. Tranah’s current research program is focused on identifying inherited and acquired genetic factors that impact aging and disease with the goal of revolutionizing risk assessment and identifying widely applicable and inexpensive genomic tests that identify persons who would benefit from specific pharmacologic and behavioral treatments to prevent disability and disease.
Next-generation sequencing (NGS) technology is increasingly being adopted as an essential research and development tool in plant and animal genomics. As accessibility and affordability continue to improve, NGS is being used for marker-assisted selection (MAS) to accelerate plant breeding and selection, as well as in transcriptomics, plant or animal-pathogen interactions and epigenetics. We will present a highly multiplexed novel targeted sequencing genotyping solution that is cost-effective, flexible and features a simple workflow.Read More